IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+2.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$903M
AUM Growth
+$903M
(-20%)
Cap. Flow
-$189M
Cap. Flow
% of AUM
-20.9%
Top 10 Holdings %
Top 10 Hldgs %
48.7%
Holding
109
New
26
Increased
18
Reduced
25
Closed
31
Top Buys
| 1 |
Elevance Health
ELV
|
$28.3M |
| 2 |
Novartis
NVS
|
$27.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$22.6M |
| 4 |
Baxter International
BAX
|
$17.1M |
| 5 |
Ascendis Pharma
ASND
|
$15.6M |
Top Sells
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Eli Lilly
LLY
|
$29.3M |
| 4 |
Intuitive Surgical
ISRG
|
$20.9M |
| 5 |
CVS Health
CVS
|
$20.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $118M | 12.58% | 1,550,000 | – | – |
|
2
Boston Scientific
BSX
$156B
| $65.6M | 6.98% | 650,000 +100,000 | +18% | +$10.1M |
|
3
Cytokinetics
CYTK
$4.23B
| $44.2M | 4.7% | 1,100,000 +100,000 | +10% | +$4.02M |
|
4
Tenet Healthcare
THC
$16.3B
| $37M | 3.94% | 275,000 -125,000 | -31% | -$16.8M |
|
|
5
Mineralys Therapeutics
MLYS
$1.03B
| $36.5M | 3.89% | 2,300,000 +1,425,000 | +163% | +$22.6M |
|
|
6
Elevance Health
ELV
$71.8B
| $28.3M | 3.01% | +65,000 | New | +$28.3M |
|
|
7
Novartis
NVS
$245B
| $27.9M | 2.97% | +250,000 | New | +$27.9M |
|
8
Vera Therapeutics
VERA
$1.38B
| $27.6M | 2.94% | 1,150,000 | – | – |
|
9
Encompass Health
EHC
$12.3B
| $27.3M | 2.91% | 270,000 -30,000 | -10% | -$3.04M |
|
10
Medtronic
MDT
$119B
| $27M | 2.87% | 300,000 +150,000 | +100% | +$13.5M |
|
11
Gilead Sciences
GILD
$140B
| $19.6M | 2.09% | 175,000 -25,000 | -13% | -$2.8M |
|
|
12
Baxter International
BAX
$12.7B
| $17.1M | 1.82% | +500,000 | New | +$17.1M |
|
13
Fresenius Medical Care
FMS
$15.1B
| $16.9M | 1.8% | 680,000 +80,000 | +13% | +$1.99M |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $16.6M | 1.77% | 150,000 -10,000 | -6% | -$1.11M |
|
|
15
Ascendis Pharma
ASND
$11.8B
| $15.6M | 1.66% | +100,000 | New | +$15.6M |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $14.9M | 1.58% | 675,000 +125,000 | +23% | +$2.75M |
|
17
BrightSpring Health Services
BTSG
$4.2B
| $14M | 1.49% | 775,000 -175,000 | -18% | -$3.17M |
|
|
18
CVS Health
CVS
$92.8B
| $13.6M | 1.44% | 200,000 -300,000 | -60% | -$20.3M |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $13.5M | 1.44% | 50,000 +5,000 | +11% | +$1.35M |
|
20
uniQure
QURE
$896M
| $13.3M | 1.41% | 1,250,000 +150,000 | +14% | +$1.59M |
|
|
BPMC
21
DELISTED
Blueprint Medicines
BPMC
| $12.8M | 1.37% | 145,000 -130,000 | -47% | -$11.5M |
|
22
AbbVie
ABBV
$372B
| $12.6M | 1.34% | +60,000 | New | +$12.6M |
|
23
RadNet
RDNT
$5.52B
| $12.4M | 1.32% | +250,000 | New | +$12.4M |
|
24
GE HealthCare
GEHC
$33.7B
| $12.1M | 1.29% | +150,000 | New | +$12.1M |
|
25
Krystal Biotech
KRYS
$4.27B
| $10.8M | 1.15% | 60,000 +5,000 | +9% | +$902K |
|